NCT06155994View on ClinicalTrials.gov

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions

Neuroendocrine Tumors

Interventions

DRUG

68Ga-DOTA-MGS5

intravenous administration

Trial Locations (1)

6020

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Medical University Innsbruck

OTHER